王林啸

研究方向：人工智能、CADD及网络药理赋能药物发现及先导优化

电子邮箱：wanglinxiao542@163.com

简要介绍：主持省级项目3项，市厅级项目1项，校级2项，以第一/通讯发表SCI论文 20余篇，以第一指导老师指导学生获省级国家级互联网、挑战杯、大学生药苑论坛等近20项，含全国特等奖、国银和国铜等；以第一指导老师指导本科生国家级创新/创业课题2项，校级2项；以副主编出版教材1部；为江西省医学会医学信息学会 常务委员、江西省研究型医院学会肿瘤学分会青年委员会 委员；获江西省优秀创新创业导师称号、江西省自然科学二等奖1项（第四）。

代表成果：

1. Wang, Linxiao; Zhang, Qian; Wang, Zhe, Design, synthesis, docking, molecular dynamics and bioevaluation studies on novel N-methylpicolinamide and thienopyrimidine derivatives with inhibiting NF-κB and TAK1 activities: Cheminformatics tools RDKit applied in drug design, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2021, 10.1016/j.ejmech.2021.113576.

2. An, Yufeng; Lv, Xinya; Xu, Shidi, Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy(2006-present), EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 10.1016/j.ejmech.2025.117268.

3. Huang, Xiaoling; Xu, Shidi; An, Yufeng, Revealing 5-(3,5-difluorobenzyl)-1H-indazole as the active pharmacophore of ALK/ROS1 dual inhibitors through theoretical calculations and biological activity evaluations, BIOORGANIC CHEMISTRY, 2025, 10.1016/j.bioorg.2024.108014.

4. Wang, Linxiao; Huang, Xiaoling; Xu, Shidi, Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R, BMC CHEMISTRY, 2024, 10.1186/s13065-024-01279-z.

5. 新型c-Met/EGFR靶向抗癌药物研发与抗突变耐药机制研究，江西省自然科学二等奖（第四），2023.